•• Graus F, Vogrig A, Muñiz-Castrillo S, Antoine JCG, Desestret V, Dubey D, Giometto B, Irani SR, Joubert B, Leypoldt F, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflammation. 2021;8:e1014. Proposed new diagnostic criteria for diagnosis of paraneoplastic neurologic syndromes by a group of experts.

Zoccarato M, Grisold W, Grisold A, Poretto V, Boso F, Giometto B. Paraneoplastic Neuropathies: What’s New Since the 2004 Recommended Diagnostic Criteria. Front Neurol. 2021;12:706169.

PubMed  PubMed Central  Article  Google Scholar 

Antoine JC, Camdessanché JP. Treatment options in paraneoplastic disorders of the peripheral nervous system. Curr Treat Options Neurol. 2013;15:210–23.

PubMed  Article  Google Scholar 

Graus F, Dalmau J. Paraneoplastic neuropathies. Curr Opin Neurol. 2013;26:489–95.

CAS  PubMed  Article  Google Scholar 

Keime-Guibert F, Graus F, Broët P, Reñé R, Molinuevo JL, Ascaso C, Delattre JY. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology. 1999;53:1719–23.

CAS  PubMed  Article  Google Scholar 

• Goyal NA. Immune-Mediated Myopathies Continuum (Minneap Minn). 2019;25:1564–85. Review article on the different immune myopathies including the ones associated with malignancies.

Google Scholar 

Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010;67:330–5.

PubMed  Article  Google Scholar 

Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013;65:2954–62.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, Danoff SK, Johnson C, Christopher-Stine L, Mammen AL. Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care Res. 2017;69:1771–6.

CAS  Article  Google Scholar 

Gono T, Kuwana M. Dermatomyositis-Associated Autoantibodies: TIF1-γ, NXP2, and MDA5. In Managing Myositis. Edited by: Springer International Publishing. 2020;193–198.

Amato AA, Russell JA. Neuromuscular Disorders edn 2nd: McGraw Hill. 2016.

Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, Callen JP, Fiorentino D. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts. Medicine (Baltimore). 2018;97: e9639.

Article  Google Scholar 

Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PAE, Tanasescu R, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol. 2011;18:19-e13.

CAS  PubMed  Article  Google Scholar 

Selva-O’Callaghan A, Grau JM, Gámez-Cenzano C, Vidaller-Palacín A, Martínez-Gómez X, Trallero-Araguás E, Andía-Navarro E, Vilardell-Tarrés M. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med. 2010;123:558–62.

PubMed  Article  Google Scholar 

Mckeon A. Positron Emission Tomography-Computed Tomography in Paraneoplastic Neurologic Disorders. Arch Neurol. 2010;67:322.

PubMed  Article  Google Scholar 

Lancaster E. Paraneoplastic Disorders. CONTINUUM: Lifelong Learn Neurol. 2015;21:452–475.

Kang EH, Lee SJ, Ascherman DP, Lee YJ, Lee EY, Lee EB, Song YW. Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis. Rheumatology. 2016;55:1631–41.

CAS  PubMed  Article  Google Scholar 

Dalakas MC. Immunotherapy of Inflammatory Myopathies: Practical Approach and Future Prospects. Curr Treat Options Neurol. 2011;13:311–23.

PubMed  Article  Google Scholar 

Bunch TW. Prednisone and azathioprine for polymyositis. Long-term followup Arthritis & Rheumatism. 1981;24:45–8.

CAS  Article  Google Scholar 

Vencovsky J. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29:95–102.

CAS  PubMed  Article  Google Scholar 

Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–7.

CAS  PubMed  Article  Google Scholar 

Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403–7.

CAS  PubMed  Article  Google Scholar 

Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: Present approaches and a look to the future. Neuromuscul Disord. 2006;16:223–36.

PubMed  Article  Google Scholar 

Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. 2018;28:913–21.

CAS  PubMed  Article  Google Scholar 

Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, Kawaguchi Y, Jinnin M, Muro Y, Ishihara S, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Mod Rheumatol. 2019;29:1–19.

PubMed  Article  Google Scholar 

Distad BJ, Amato AA, Weiss MD. Inflammatory Myopathies. Curr Treat Options Neurol. 2011;13:119–30.

PubMed  Article  Google Scholar 

Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51:638–56.

CAS  PubMed  Article  Google Scholar 

Raghu P, Manadan AM, Schmukler J, Mathur T, Block JA. Pulse Dose Methylprednisolone Therapy for Adult Idiopathic Inflammatory Myopathy. Am J Ther. 2015;22:244–7.

PubMed  Article  Google Scholar 

van de Vlekkert J, Hoogendijk JE, de Haan RJ, Algra A, van der Tweel I, van der Pol WL, Uijtendaal EV, de Visser M. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord. 2010;20:382–9.

PubMed  Article  Google Scholar 

Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, Mccrosky S. A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis. N Engl J Med. 1993;329:1993–2000.

CAS  PubMed  Article  Google Scholar 

Gelardi C, Paolini L, Danieli MG. Subcutaneous immunoglobulin G in idiopathic inflammatory myopathies: therapeutic implications. Isr Med Assoc J. 2014;16:646–7.

PubMed  Google Scholar 

Hachulla E, Benveniste O, Hamidou M, Mouthon L, Schleinitz N, Lozeron P, Léger JM, Vial C, Viala K. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. Int J Neurosci. 2017;127:516–23.

CAS  PubMed  Article  Google Scholar 

Barsotti S, Lundberg IE. Current Treatment for Myositis. Current Treatment Options in Rheumatology. 2018;4:299–315.

PubMed  PubMed Central  Article  Google Scholar 

Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, Thornton BC, Burgess SH, Plotz PH, Miller FW. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 1998;41:392–9.

CAS  PubMed  Article  Google Scholar 

Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med. 1980;92:365–369.

Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129–37.

PubMed  Article  Google Scholar 

Witte AS, Cornblath DR, Schatz NJ, Lisak RP. Monitoring azathioprine therapy in myasthenia gravis. Neurology. 1986;36:1533–4.

CAS  PubMed  Article  Google Scholar 

Thomas CW, Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis. 2003;9:237–45.

PubMed  Article  Google Scholar 

Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314–24.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology. 2017;56:26–36.

CAS  PubMed  Article  Google Scholar 

Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, Van Assen S, Bijl M, Breedveld FC, D’Amelio R, Dougados M, Kapetanovic MC, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79:39–52.

CAS  PubMed  Article  Google Scholar 

Boekel L, Wolbink GJ. Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients. The Lancet Rheumatol. 2021.

Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Allenbach Y, Amato A, Aussey A, Benveniste O, De Bleecker J, De Groot I, et al. 224th ENMC International Workshop: Neuromuscular Disorders. 2018;28:87–99.

Lim J, Rietveld A, De Bleecker JL, Badrising UA, Saris CGJ, Van Der Kooi AJ, De Visser M. Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurology - Neuroimmunology Neuroinflammation. 2019;6: e513.

PubMed  Article  Google Scholar 

Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16:689–701.

CAS  PubMed  Article  Google Scholar 

Liu R, Fenves AZ, Champion SN, Dau J. Seronegative necrotizing autoimmune myopathy with favorable response to intravenous immunoglobulin. Baylor University Medical Center Proceedings. 2021;34:481–3.

PubMed  PubMed Central  Article